| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ASMB | Common Stock | Award | $0 | +35K | +39.77% | $0.00 | 123K | May 22, 2023 | Direct | F1, F2 |
| transaction | ASMB | Common Stock | Sale | -$6.83K | -6.56K | -5.33% | $1.04 | 116K | May 23, 2023 | Direct | F3, F4 |
| Id | Content |
|---|---|
| F1 | Represents shares of common stock issuable under a performance-based restricted stock unit award dated July 22, 2021. On May 22, 2023, the performance-based vesting conditions were achieved. These shares of common stock vest in two equal installments, assuming continuous service on each vesting date, as follows: May 22, 2023 and May 22, 2024. |
| F2 | Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on May 12, 2023. |
| F3 | The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.07, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. |